Organon (NYSE: OGN), a global company dedicated to improving women's health, has completed the acquisition of Dermavant Sciences Ltd., a company specialized in immunodermatology. This acquisition includes VTAMA® cream (tapinarof) 1%, an innovative topical treatment approved in the United States for plaque psoriasis and pending approval for atopic dermatitis.
VTAMA cream represents an advance in the treatment of chronic skin conditions, offering a non-biologic and non-steroidal solution for patients suffering from mild to severe plaque psoriasis. Endorsed by the FDA, VTAMA has no restrictions on use regarding location and duration, which allows its application to extensive areas of the skin without worrying about serious adverse effects.
Additionally, the FDA is currently reviewing a supplemental application for the use of VTAMA in atopic dermatitis, also known as eczema, in both adults and children over two years of age. An official decision is expected in the fourth quarter of 2024, which would expand the scope of this treatment to another of the most prevalent inflammatory skin conditions.
Dermatological Innovation in the United States and Global Potential
Kevin Ali, CEO of Organon, commented on the impact of this acquisition: "The future of dermatology depends on innovative treatments like VTAMA. Dermavant's experience in immunodermatology strengthens our ability to provide millions of people with a safe and effective option against chronic skin diseases". Additionally, Ali highlighted that the acquisition marks a new chapter for Organon, expanding its presence in the dermatological sector and strengthening its commitment to health innovation.
For his part, Mayukh Sukhatme, president of Roivant, expressed his satisfaction: "Collaboration with Organon will maximize VTAMA's reach so that its impact reaches patients around the world. This alliance reflects our shared commitment to addressing unmet medical needs in dermatology".
About VTAMA® and Its Clinical Benefits
VTAMA is administered once daily and has demonstrated efficacy and safety in clinical studies, such as the PSOARING trials for psoriasis and ADORING for atopic dermatitis. Reported adverse effects include folliculitis, nasopharyngitis, and contact dermatitis, with no significant warnings for prolonged use.
Organon's Expansion in Dermatological Health Care
With the incorporation of VTAMA, Organon strengthens its mission to develop innovative health solutions. Through this expansion in dermatology, Organon reiterates its commitment to developing effective and accessible treatments that improve the quality of life of patients with chronic skin diseases.
With information from Businesswire